直 Japanese PDF Font
  • Our Professionals
  • Our Work
  • Our Insights
  • Offices
  • Firm
  • Careers
Finnegan
  • Articles & Books
    • Ad Law Buzz Blog
    • At the PTAB Blog
    • European IP Blog
    • Federal Circuit IP Blog
    • INCONTESTABLE® Blog
    • Prosecution First Blog
  • Events & Webinars
  • IP Updates
  • Podcasts
    • AI + Finnegan
    • AI + Copyright
    • AI + Patent
    • AI + Privacy
    • AI + Trade Secrets
    • AI + Trademark
  • Unified Patent Court (UPC) Hub

At the PTAB Blog

Year One of the Transitional Program for CBM Patents: Petitions and Promise

September 18, 2013

Since coming into force on September 16, 2012, the Transitional Program for Covered Business Method (“CBM”) Patents under section 18 of the AIA has seen steady growth. Fifty-three petitions have been filed in the program’s first year of operation (see inset below). Liberty Mutual leads with 10 petitions—other major players including Groupon (5), Apple (4), Fidelity (4), and SAP (3).

The Board has taken action in 18 petitions (see inset below), granting 12, denying 3, and dismissing 3, following joint motions after settlement of related district court litigation. Novelty and obviousness dominate the grounds for review, with a handful of granted petitions seeking review under either 35 U.S.C. §§ 101 or 112. The Board has issued only one final written decision, however many more can be confidently expected given the one-year statutory deadline for concluding a CBM. See 35 U.S.C. § 326(a)(11).

CBM-Filings-and-PTAB-Action

The Board has taken pains to address the jurisdictional scope of CBM proceedings, which may only be instituted against “covered business method patents.” See AIA §18; 37 C.F.R. § 42.301. In its decision instituting the first ever CBM proceeding, the Board concluded that CBMs include “patents claiming activities that are financial in nature, incidental to a financial activity, or complementary to a financial activity.” This admittedly broad interpretation is currently being challenged under the Administrative Procedure Act in the Eastern District of Virginia.

Board decisions have also construed the scope of “technological inventions,” which the AIA explicitly shields from CBM proceedings. The Board’s interpretation of 37 C.F.R. § 42.301(b), requires patent owners seeking cover of the exception to show that the claimed invention includes “[a] ‘technological feature’ that is novel and unobvious,” and which also “solves a technical problem using a technical solution.”

Finally, this first year of CBM proceedings has seen developments in the standard for obtaining district court stays, filing strategies addressing the strict 80-page word limit for petitions, protective orders, and the availability of CBM proceedings for declaratory judgment plaintiffs. And certainly with the number of cases awaiting Board action, the coming year promises to elucidate whether CBM proceedings will be a robust forum for resolving patent disputes.

Copyright © 2013 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP. 

DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. Additional disclaimer information. 

Related Insights

Conference

7th International Conference on Biofuels and Bioenergy

June 25-26, 2026

Edinburgh

Conference

IPBC Global 2026

June 15-17, 2026

San Diego

Conference

17th Summit on Biosimilars & Innovator Biologics

June 2-3, 2026

New York

At the PTAB Blog

Consistency Is Key – USPTO Issues Three New Informative Decisions

May 29, 2026

At the PTAB Blog

Discretion All the Way Down: USPTO Uses a Discretionary IPR Denial to Justify a    
§ 325(d) EPR Denial

May 28, 2026

Articles

Colorado Replaces Landmark AI Act: An Overview of the New SB 26-189 Framework

May 26, 2026

At the PTAB Blog

IPR and PGR Statistics for Final Written Decisions Issued in March and April 2026

May 26, 2026

At the PTAB Blog

Claim Disclaimer Derails Instituted IPR in Freightcar America

May 26, 2026

At the PTAB Blog

Before the Holding, the Message: Director Squires Uses Magnolia Medical to Outline PTAB Discretionary Denial Policy Changes

May 20, 2026

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • Privacy
  • Disclaimer
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP